Retatrutide vs Semaglutide and Tirzepatide: What the New Phase 3 Data Really Show
No head-to-head trial has compared retatrutide against semaglutide or tirzepatide. Retatrutide’s TRIUMPH-2 Phase 3 results (Eli Lilly, September 2026) come from its own placebo-controlled trial in type 2 diabetes — so every cross-drug comparison is indirect and must be read with that limit.
What TRIUMPH-2 actually was
TRIUMPH-2 evaluated retatrutide — an investigational triple GIP/GLP-1/glucagon receptor agonist — in adults with type 2 diabetes and obesity or overweight, and Eli Lilly released detailed results on September 29, 2026. Because TRIUMPH-2 contained no semaglutide or tirzepatide arm, placing its results beside STEP or SURMOUNT results compares different trials, populations and durations; the table below keeps each figure attached to its own trial so the comparison stays honest.
| Drug | Trial | Population | Duration | Mean weight change | Source |
|---|---|---|---|---|---|
| Semaglutide | STEP 1 (Phase 3) | 1,961 adults with overweight or obesity | 68 weeks | −14.9% (vs −2.4% placebo) | Wilding et al., New England Journal of Medicine, 2021 |
| Tirzepatide | SURMOUNT-1 (Phase 3) | 2,539 adults with overweight or obesity | 72 weeks | −20.9% at the highest dose (vs −3.1% placebo) | Jastreboff et al., New England Journal of Medicine, 2022 |
| Retatrutide | TRIUMPH-2 (Phase 3) | Adults with type 2 diabetes and obesity or overweight | 80 weeks | 12.7% reduction with retatrutide 4 mg; 19.1% reduction with retatrutide 9 mg; 20.8% reduction with retatrutide 12 mg (vs 4.0% reduction with placebo) | Eli Lilly TRIUMPH-2 results, released September 29, 2026, as reported in this article |
Why retatrutide is different
Retatrutide is designed to activate three metabolic hormone pathways in a single molecule:
- GIP
- GLP-1
- glucagon
Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors.
Mechanistic differences alone do not prove clinical superiority. The meaningful question is what happens in well-designed trials.
TRIUMPH-2: the key Phase 3 results
TRIUMPH-2 randomized 1,152 adults with type 2 diabetes and obesity or overweight to retatrutide 4 mg, 9 mg, or 12 mg once weekly or placebo for 80 weeks.
Under Lilly’s efficacy estimand, average body-weight changes were:
- 12.7% reduction with retatrutide 4 mg
- 19.1% reduction with retatrutide 9 mg
- 20.8% reduction with retatrutide 12 mg
- 4.0% reduction with placebo
Among participants with baseline BMI of 35 or greater, the 12 mg group lost an average of 23.4% of body weight.
More than half of participants in the 12 mg group no longer met BMI criteria for obesity by the end of the trial.
What happened to glycemic control?
A1C also improved substantially.
Average A1C reductions were 1.4 percentage points with 4 mg, 1.6 percentage points with 9 mg, and 1.9 percentage points with 12 mg.
Up to 40.0% of participants reached an A1C below 5.7%.
Why cross-trial comparisons can be misleading
It is tempting to place retatrutide, semaglutide, and tirzepatide weight-loss percentages side by side, but such comparisons can mislead.
That is not scientifically sound unless the drugs were tested head-to-head under the same protocol.
Different trials can vary in:
- baseline body weight
- diabetes status
- duration
- dose-escalation schedule
- background therapy
- estimand
- handling of discontinuations
- population characteristics
The stronger comparison will come from dedicated head-to-head trials.
A direct retatrutide-versus-semaglutide trial is underway
The Canadian Clinical Trial Search Portal lists TRANSCEND-T2D-2, a Phase 3 randomized study comparing once-weekly retatrutide with once-weekly semaglutide in adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor.
That trial should provide much more useful comparative evidence than independent trial percentages.
What about retatrutide versus tirzepatide?
Retatrutide and tirzepatide differ mechanistically because retatrutide adds glucagon receptor activation to GIP and GLP-1 activity.
However, mechanism should not be mistaken for an outcome.
Until sufficiently informative head-to-head data are available, claims that retatrutide is categorically better than tirzepatide remain unsupported.
Cardiometabolic effects beyond body weight
In TRIUMPH-2, Lilly also reported average reductions at the highest retatrutide dose in triglycerides, non-HDL cholesterol, blood pressure, waist circumference, and high-sensitivity C-reactive protein.
These findings are scientifically important because obesity treatment is increasingly being evaluated by broader cardiometabolic outcomes, not weight loss alone.
Safety and tolerability
The most common adverse events were gastrointestinal, particularly diarrhea, nausea, constipation, and vomiting.
Adverse-event discontinuation rates were 3.8%, 11.6%, and 7.7% in the 4 mg, 9 mg, and 12 mg groups, respectively.
Safety interpretation should continue to evolve as larger and longer studies are completed.
Why the wider retatrutide program matters
Retatrutide is being studied across multiple conditions, including obesity, type 2 diabetes, cardiovascular disease, and obstructive sleep apnea.
This matters because the long-term value of metabolic therapies may ultimately be judged by effects on major health outcomes, not weight loss alone.
Retatrutide is still investigational
Despite growing interest, retatrutide remains investigational and is not currently approved by regulatory agencies for public use.
The new Phase 3 results strengthen the evidence base, but regulatory review and additional clinical data remain necessary.
What the new evidence changes
TRIUMPH-2 does not answer every question about how retatrutide compares with semaglutide or tirzepatide.
What it does show is that triple agonism has now produced substantial weight and glycemic effects in a large Phase 3 population with type 2 diabetes.
The next important step is comparative evidence.
That is why direct trials such as TRANSCEND-T2D-2 may ultimately be more informative than cross-trial percentages.
Frequently asked questions
What is retatrutide?
Retatrutide is an investigational once-weekly triple agonist that activates GIP, GLP-1, and glucagon receptors.
How much weight loss occurred in TRIUMPH-2?
Under the efficacy estimand, participants receiving 12 mg lost an average of 20.8% of body weight over 80 weeks.
Is retatrutide stronger than semaglutide?
Separate trial percentages cannot establish superiority. A dedicated Phase 3 retatrutide-versus-semaglutide trial is underway.
Is retatrutide better than tirzepatide?
There is not enough direct comparative evidence to make that conclusion. Retatrutide has a different mechanism, but mechanism is not proof of superior outcomes.
Is retatrutide approved?
No. Retatrutide remains investigational and is not approved for public use.
Sources
- Eli Lilly TRIUMPH-2 top-line results (Investor Relations)
- TRANSCEND-T2D-2 — Canadian Clinical Trial Search Portal
- What to know about retatrutide — Eli Lilly
This article is for educational purposes and summarizes publicly available clinical-trial information. It is not medical advice.
For laboratory research use only. Not for human consumption.